Plasma exchange (PLEX) in addition to standard immunosuppressive treatment in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AVV) remains controversial. The aim of this study is to evaluate the effect of PLEX on AVV outcomes.
Literature search was performed using Medline, Scopus, Cochrane Central Register of Controlled Trials, Clinicaltrials.gov databases, and Google Scholar. The statistical meta-analysis and leave-one-out analysis were conducted using the Review Manager 5.3 and Open Meta-Analyst software, respectively.
Ten studies were included in the meta-analysis comprising 1235 patients; 633 received conventional treatment and 602 were treated with PLEX in conjunction with induction therapy. PLEX was not associated with lower rates of either mortality at 3 (RR: 0.79, 95% CI: 0.19–3.25) and 12 months (RR: 0.73, 95% CI: 0.40–1.34) or ESRD at 3 (RR: 0.30, 95% CI: 0.30–2.42) and 12 months (RR: 1.32, 95% CI: 0.53–3.25). Similarly, no differences were captured concerning disease relapses (RR: 0.92, 95% CI: 0.62–1.36), the incidence of infections (RR: 1.05, 95% CI: 0.63–1.76), and severe adverse effects (RR: 1.04, 95% CI: 0.59–1.81). Time-to-event analysis revealed lower incidence of ESRD (HR: 0.71, 95% CI: 0.55–0.92) among patients who received PLEX, while the overall mortality was similar (HR: 0.96, 95% CI: 0.72–1.29) between the two groups.
The present meta-analysis does not support the wide use of PLEX for the management of AAV in routine clinical practice. Future well-designed randomized controlled trials focusing on specific disease-related manifestations are necessary to reach firm conclusions about the potential efficacy of PLEX.
• PLEX is not widely recommended for the management of ANCA-associated vasculitis.
• PLEX performance may reduce the overall incidence of ESRD in severe ANCA-associated vasculitis.
• Well-designed randomized controlled trials focusing on specific disease-related manifestations are necessary to reach firm conclusions about the potential efficacy of PLEX on AAV-related outcome.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Jennette JC (2013) Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol 17:603–606
Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CGM, Mccluskey RT, Sinico RA, Rees AJ, Es LAV, Waldherr RÜD, Wiik A (1994) Nomenclature of systemic vasculitides. Arthritis Rheum 37(2):187–192
Yang JJ, Jennette JC, Falk RJ (1994) Immune complex glomerulonephritis is induced in rats immunized with heterologous myeloperoxidase. Clin Exp Immunol 97(3):466–473 Available from: http://www.ncbi.nlm.nih.gov/pubmed/8082301 [cited 2019 Nov 17]
Little MA, Al-Ani B, Ren S, Al-Nuaimi H, Leite M, Alpers CE et al (2012) Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system. PLoS One 11:7(1)
Schlieben DJ, Korbet SM, Kimura RE, Schwartz MM, Lewis EJ (2005) Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. Am J Kidney Dis 45(4):758–761
Walsh M (2014) Plasma exchange in antineutrophil cytoplasm antibody-associated vasculitis. Curr Opin Nephrol Hypertens 23(6):555–559
Bosch X, Guilabert A, Espinosa G, Mirapeix E (2007) Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA 298(6):655–669 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17684188 [cited 2019 Nov 17]
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363(3):221–232
Jones RB, Tervaert JWC, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR, European Vasculitis Study Group (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363(3):211–220
Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JWC, Dadoniené J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349(1):36–44
Moiseev S, Novikov P, Jayne D, Mukhin N (2017) End-stage renal disease in ANCA-associated vasculitis. Nephrol Dial Transplant 32(2):248–253
Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C et al (2010) Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 69(6):1036–1043 Available from: http://www.ncbi.nlm.nih.gov/pubmed/19574233 [cited 2019 Nov 17]
Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel PA, Mills J, Mooney J, Segelmark M, Tesar V, Westman K, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C (2016) EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75(9):1583–1594
Walsh M, Merkel PA, Peh C-A, Szpirt WM, Puéchal X, Fujimoto S, Hawley CM, Khalidi N, Floßmann O, Wald R, Girard LP, Levin A, Gregorini G, Harper L, Clark WF, Pagnoux C, Specks U, Smyth L, Tesar V, Ito-Ihara T, de Zoysa JR, Szczeklik W, Flores-Suárez LF, Carette S, Guillevin L, Pusey CD, Casian AL, Brezina B, Mazzetti A, McAlear C, Broadhurst E, Reidlinger D, Mehta S, Ives N, Jayne DRW, PEXIVAS Investigators (2020) Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 382(7):622–631
Cortazar FB, Niles JL (2020) The fate of plasma exchange and glucocorticoid dosing in ANCA-associated vasculitis after PEXIVAS. Am J Kidney Dis Available from: https://linkinghub.elsevier.com/retrieve/pii/S0272638620306156 [cited 2020 May 23]
Hohenstein B, Schettler V, Groot K (2020) With reasonable doubt: plasma exchange in <scp>PEXIVAS</scp>. Ther Apher Dial:1744–9987.13491 Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/1744-9987.13491 [cited 2020 May 23]
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 339:b2700
Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 343:d5928
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 355:i4919
Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ. 327(7414):557–560
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 8:16
Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815–2834
Wallace BC, Schmid CH, Lau J, Trikalinos TA (2009) Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol 9(1):80
Nakamura T, Matsuda T, Kawagoe Y, Ueda Y, Ebihara I, Koide H (2004) Plasmapheresis with immunosuppressive therapy vs immunosuppressive therapy alone for rapidly progressive anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis. Nephrol Dial Transplant 19(7):1935–1937
Frausová D, Hrušková Z, Lánská V, Lachmanová J, Tesař V (2016) Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study. Arthritis Res Ther 18:168
Hruskova Z, Casian A, Konopasek P, Svobodova B, Frausova D, Lanska V, Tesar V, Jayne DRW (2013) Long-term outcome of severe alveolar haemorrhage in ANCA-associated vasculitis: a retrospective cohort study. Scand J Rheumatol 42(3):211–214
Jayne DRW, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage COS, Sinico RA, Stegeman CA, Westman KW, van der Woude FJ, de Lind van Wijngaarden RAF, Pusey CD (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18(7):2180–2188
Walsh M, Casian A, Flossmann O, Westman K, Höglund P, Pusey C, Jayne DR, European Vasculitis Study Group (EUVAS) (2013) Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 84(2):397–402
Szpirt WM, Heaf JG, Petersen J (2011) Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener’s granulomatosis—a clinical randomized controlled trial. Nephrol Dial Transplant 26(1):206–213
Zäuner I, Bach D, Braun N, Krämer BK, Fünfstück R, Helmchen U, Schollmeyer P, Böhler J (2002) Predictive value of initial histology and effect of plasmapheresis on long-term prognosis of rapidly progressive glomerulonephritis. Am J Kidney Dis 39(1):28–35
Frasca GM, Soverini ML, Falaschini A, Tampieri E, Vangelista A, Stefoni S (2003) Plasma exchange treatment improves prognosis of antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis: a case-control study in 26 patients from a single center. Ther Apher Dial 7(6):540–546
Dhaun N, Saunders A, Bellamy CO, Gallardo RM, Manson L, Kluth DC (2015) Benefits of an expanded use of plasma exchange for anti-neutrophil cytoplasmic antibody-associated vasculitis within a dedicated clinical service clinical rheumatology and osteoporosis. BMC Musculoskelet Disord 16(1):1–10. https://doi.org/10.1186/s12891-015-0796-7
Solar-Cafaggi D, Atisha-Fregoso Y, Hinojosa-Azaola A (2016) Plasmapheresis therapy in ANCA-associated vasculitides: a single-center retrospective analysis of renal outcome and mortality. J Clin Apher 31(5):411–418
de Joode AA, Sanders JSF, Smid WM, Stegeman CA (2014) Plasmapheresis rescue therapy in progressive systemic ANCA-associated vasculitis: single-center results of stepwise escalation of immunosuppression. J Clin Apher 29(5):266–272
Gregersen JW, Kristensen T, Krag SRP, Birn H, Ivarsen P (2012) Early plasma exchange improves outcome in PR3-ANCA-positive renal vasculitis. Clin Exp Rheumatol 30(1 Suppl 70):S39–S47
Walsh M, Catapano F, Szpirt W, Thorlund K, Bruchfeld A, Guillevin L, Haubitz M, Merkel PA, Peh CA, Pusey C, Jayne D (2011) Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis 57(4):566–574
Philip J, Sarkar RS, Pathak A (2013) Adverse events associated with apheresis procedures: Incidence and relative frequency. Asian J Transfus Sci 7(1):37–41
Plasmapheresis. In: Pocket companion to Brenner and Rector’s the kidney. Elsevier; 2011 [cited 2019 Nov 20]. p. 777–88. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9781416066408000373
Wing EJ, Bruns FJ, Fraley DS, Segel DP, Adler S (1980) Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis. JAMA J Am Med Assoc 244(21):2423–2426
Cartin-Ceba R, Diaz-Caballero L, Al-Qadi MO, Tryfon S, Fervenza FC, Ytterberg SR et al (2016) Diffuse alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: predictors of respiratory failure and clinical outcomes. Arthritis Rheumatol (Hoboken, NJ) 68(6):1467–1476 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26713723 [cited 2019 Nov 22]
Research involving human participants and/or animals
For this type of study, formal consent is not required.
This article does not contain any studies with human participants performed by any of the authors.
Informed consent was not required since no patients participated the study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Bellos, I., Michelakis, I. & Nikolopoulos, D. The role of plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Clin Rheumatol 40, 1447–1456 (2021). https://doi.org/10.1007/s10067-020-05390-z
- Plasma exchange